S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
RXRX · Recursion Pharmaceuticals, Inc. Class A
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Recursion Pharmaceuticals Inc (RXRX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$3.63
-0.03
(-0.82%)
● At close: October 21 at 4:00:00 PM EDT
$3.60
-0.04
(-1.10%)
After-Hours:
7:53:56 PM EDT
DAY'S RANGE
$3.63
$3.56
$3.75
52-WEEK RANGE
$3.63
$2.77
$7.18
What's happening
- RXRX is down 0.82% today, trading at $3.63. — Live quote
- Volume today (991,058) is well below its 3-month average of 22,173,680. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 21 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.25 actual vs. $-0.24 estimated (-4.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 6
Hold 5
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RXRX
-10.51%
vs S&P 500
-23.29%
1-YEAR RETURN
RXRX
-45.21%
vs S&P 500
-59.77%
6-MONTH RETURN
RXRX
+1.67%
3-MONTH RETURN
RXRX
+18.83%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.25
Est. $-0.24
MISS -4.7%
2026-04-26 (Q1 2026)
$-0.22
Est. $-0.28
BEAT +20.5%
2026-01-26 (Q4 2025)
$-0.21
Est. $-0.32
BEAT +34.8%
2025-10-26 (Q3 2025)
$-0.36
Est. $-0.38
BEAT +4.6%
Valuation Measures & Ratios
Enterprise Value4$1.66B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)39.89
Price / Book72.13
EV4 / Revenue30.20
EV4 / EBITDA—
Profit Margin-945.92%
Operating Margin-991.72%
Return on Equity (ROE8)-50.41%
Return on Assets (ROA9)-38.25%
Avg Volume (3M)22,173,680
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.92B | $1.64B | $2.20B | $2.12B | $2.14B |
| P/E | -3.30 | -2.51 | -3.47 | -3.73 | -4.39 |
| Price/Sales | 49.90 | 35.95 | 33.69 | 28.43 | 31.00 |
| Price/Book | 2.10 | 1.60 | 2.10 | 2.30 | 2.29 |
| EV/Revenue | 35.74 | 21.60 | 23.57 | 21.38 | 23.75 |
| EV/EBITDA | -2.60 | -1.69 | -2.71 | — | — |
| ROE | -63.68% | -63.83% | -60.41% | -61.77% | -52.17% |
| ROA | -48.05% | -48.83% | -45.19% | -43.60% | -37.33% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short157,938,412
Change from Prior Settlement-11.63%
% of Float—
Days to Cover (Short Ratio)6.13
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-15; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -60.1% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -945.9%. Finnhub fundamentals ↗
- Trailing 52-week price return is -45.2%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RXRX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $6.5M | $5.2M | $19.2M | $14.7M | $26.1M | $14.4M | $13.8M |
| Operating income | -$135.0M | -$128.5M | -$172.2M | -$176.2M | -$191.4M | -$98.4M | -$100.5M | -$96.3M |
| Net income | -$131.0M | -$117.5M | -$162.3M | -$171.9M | -$202.5M | -$95.8M | -$97.5M | -$91.4M |
| EPS (diluted) | $-0.25 | $-0.22 | $-0.36 | $-0.41 | $-0.50 | $-0.34 | $-0.40 | $-0.39 |
| EPS (basic) | $-0.25 | $-0.22 | $-0.36 | $-0.41 | $-0.50 | $-0.34 | $-0.40 | $-0.39 |
| Operating margin | -$1.8K | -$2.0K | -$3.3K | -$917 | -$1.3K | -$377 | -$697 | -$698 |
| Net margin | -$1.7K | -$1.8K | -$3.1K | -$894 | -$1.4K | -$367 | -$677 | -$662 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.21B | $1.34B | $1.47B | $1.40B | $1.30B | $1.31B | $1.45B | $726.5M |
| Total liabilities | $297.7M | $314.8M | $343.3M | $352.6M | $383.2M | $371.3M | $413.8M | $201.9M |
| Stockholders' equity | $915.0M | $1.02B | $1.13B | $1.05B | $919.1M | $933.9M | $1.03B | $524.6M |
| Total current assets | $603.5M | $709.6M | $812.8M | $714.1M | $587.2M | $584.1M | $714.3M | $474.2M |
| Total current liabilities | $119.9M | $129.7M | $147.7M | $155.1M | $164.0M | $142.0M | $187.5M | $108.9M |
| Cash & equivalents | $545.7M | $654.5M | $743.3M | $659.8M | $525.1M | $500.5M | $594.4M | $427.6M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | $29.3M | $24.2M | $28.6M | $29.2M | $37.3M | $32.0M | $38.1M | $42.7M |
| Property, plant & equipment | $89.6M | $95.8M | $103.9M | $111.7M | $120.0M | $126.8M | $141.1M | $84.4M |
| Goodwill | $160.3M | $160.2M | $162.2M | $162.0M | $164.3M | $158.1M | $148.9M | $52.1M |
| Intangible assets | $282.9M | $294.1M | $309.9M | $322.3M | $341.3M | $335.8M | $335.9M | $34.1M |
| Other non-current assets | $12.2M | $12.2M | $12.8M | $14.7M | $9.4M | $14.8M | $8.8M | $360.0K |
| Accounts payable | $12.7M | $20.3M | $18.1M | $13.9M | $19.3M | $25.1M | $21.6M | $2.3M |
| Accrued liabilities | $56.9M | $54.2M | $70.2M | $53.1M | $64.3M | $56.8M | $81.9M | $40.6M |
| Deferred revenue (current) | $27.6M | $32.8M | $37.6M | $47.4M | $39.7M | $39.7M | $61.8M | $49.6M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Other non-current liabilities | $2.7M | $2.0M | $2.1M | $1.0M | $1.6M | $4.8M | $4.7M | $3.0M |
| Common stock & paid-in capital | $5.0K | $5.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | $3.0K |
| Retained earnings | -$2.32B | -$2.19B | -$2.08B | -$1.97B | -$1.81B | -$1.63B | -$1.43B | -$1.25B |
| Accumulated other comprehensive income (loss) | $28.0M | $26.7M | $36.7M | $34.1M | $43.6M | $14.1M | -$7.6M | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$105.9M | -$81.1M | -$46.1M | -$117.4M | -$76.4M | -$132.0M | -$115.4M | -$59.2M |
| Investing cash flow | -$2.0M | -$338.0K | -$1.2M | -$2.5M | -$5.8M | -$7.3M | $275.5M | -$4.6M |
| Financing cash flow | -$1.3M | -$3.5M | $132.0M | $251.3M | $97.7M | $40.5M | $10.6M | $16.5M |
| Free cash flow | -$106.0M | -$81.4M | -$47.3M | -$117.6M | -$79.6M | -$133.8M | -$116.7M | -$63.8M |
| Capital expenditures | $44.0K | $258.0K | $1.2M | $243.0K | $3.1M | $1.8M | $1.3M | $4.6M |
| Depreciation & amortization | $18.2M | $19.7M | $19.5M | $21.0M | $23.8M | $19.3M | $13.0M | $7.2M |
| Share-based compensation | $19.5M | $22.2M | $23.8M | $25.2M | $26.2M | $36.1M | $30.8M | $18.3M |
| Deferred income taxes | -$3.0K | -$4.6M | -$587.0K | — | $638.0K | -$419.0K | -$1.6M | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$7.7M | $2.1M | $4.4M | -$5.9M | -$4.8M | $3.7M | $8.1M | -$1.5M |
| Purchases of investments | $0 | $0 | $0 | $2.3M | $500.0K | $1.0M | $0 | $0 |
| Debt repaid | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $44.6M | $39.8M | $10.2M |
| Operating income | -$648.1M | -$479.0M | -$350.1M | -$245.7M | -$182.8M |
| Net income | -$644.8M | -$463.7M | -$328.1M | -$239.5M | -$186.5M |
| EPS (diluted) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 |
| EPS (basic) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 |
| Operating margin | -$868 | -$814 | -$785 | -$617 | -$1.8K |
| Net margin | -$863 | -$788 | -$736 | -$601 | -$1.8K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.47B | $1.45B | $653.7M | $701.3M | $610.3M |
| Total liabilities | $343.3M | $413.8M | $190.3M | $215.5M | $67.4M |
| Stockholders' equity | $1.13B | $1.03B | $463.4M | $485.8M | $542.9M |
| Total current assets | $812.8M | $714.3M | $438.1M | $569.8M | $534.7M |
| Total current liabilities | $147.7M | $187.5M | $93.2M | $100.3M | $46.7M |
| Cash & equivalents | $743.3M | $594.4M | $391.6M | $549.9M | $285.1M |
| Marketable securities (current) | — | — | — | $0 | $231.4M |
| Accounts receivable | — | — | — | $0 | $34.0K |
| Other current assets | $28.6M | $38.1M | $40.2M | $15.9M | $7.5M |
| Property, plant & equipment | $103.9M | $141.1M | $86.5M | $88.2M | $64.7M |
| Goodwill | $162.2M | $148.9M | $52.1M | $801.0K | $801.0K |
| Intangible assets | $309.9M | $335.9M | $36.4M | $1.3M | $1.4M |
| Other non-current assets | $12.8M | $8.8M | $261.0K | $0 | $35.0K |
| Accounts payable | $18.1M | $21.6M | $4.0M | $4.6M | $2.8M |
| Accrued liabilities | $70.2M | $81.9M | $46.6M | $32.9M | $32.3M |
| Deferred revenue (current) | $37.6M | $61.8M | $36.4M | $56.7M | $10.0M |
| Long-term debt | — | — | — | — | $723.0K |
| Other non-current liabilities | $2.1M | $4.7M | $0 | — | — |
| Common stock & paid-in capital | $5.0K | $4.0K | $2.0K | $2.0K | $2.0K |
| Retained earnings | -$2.08B | -$1.43B | -$967.6M | -$639.6M | -$400.1M |
| Accumulated other comprehensive income (loss) | $36.7M | -$7.6M | $0 | $0 | -$126.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$371.8M | -$359.2M | -$287.8M | -$83.5M | -$158.6M |
| Investing cash flow | -$16.9M | $260.1M | -$10.2M | $193.2M | -$271.7M |
| Financing cash flow | $521.5M | $304.1M | $140.1M | $154.3M | $458.5M |
| Free cash flow | -$378.3M | -$372.9M | -$299.7M | -$120.6M | -$198.4M |
| Capital expenditures | $6.5M | $13.7M | $12.0M | $37.1M | $39.8M |
| Depreciation & amortization | $83.7M | $36.5M | $24.4M | $11.8M | $8.4M |
| Share-based compensation | $111.2M | $81.7M | $53.5M | $27.9M | $14.8M |
| Deferred income taxes | -$368.0K | -$1.6M | -$4.1M | $0 | — |
| Change in accounts receivable | — | — | — | — | -$114.0K |
| Change in accounts payable | -$2.6M | $6.4M | -$987.0K | $1.8M | $1.7M |
| Purchases of investments | $3.8M | $0 | $0 | — | — |
| Debt repaid | — | — | $766.0K | $90.0K | $12.8M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RXRX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-03 to 2026-10-06
Recent transactions
- Insiders have net sold 269,345 shares over the last 182 days, across 0 purchases and 10 sales.
- Most recent: Borgeson Blake (Director) — Open market sale of 50,000 shares on 2026-10-06.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)269,345 sh(10 txns)
Net Shares-269,345
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Borgeson Blake | Director | Open market sale | 2026-10-06 | 50,000 |
| HERSHBERG ROBERT | Director | Option exercise | 2026-10-06 | 25,000 |
| Dar Zavain | Director | Grant / award | 2026-10-01 | 4,607 |
| Li Dean Y | Director | Grant / award | 2026-10-01 | 3,378 |
| Taylor Ben R | Chief Financial Officer | Tax withholding | 2026-09-15 | 5,396 |
| Khan Najat | CEO and President | Open market sale | 2026-09-08 | 22,408 |
| Hallett David | Chief Scientific Officer | Tax withholding | 2026-08-17 | 26,657 |
| Bumpus Namandje | Director | Open market sale | 2026-06-18 | 3,963 |
| Michor Franziska | Director | Grant / award | 2026-06-17 | 88,424 |
| Sun Elaine D | Director | Grant / award | 2026-06-17 | 88,424 |
| Gibson Christopher | Director | Derivative conversion | 2026-06-05 | 40,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-06 | Borgeson Blake | Director | Open market sale | 50,000 | $4.84 |
| 2026-10-06 | HERSHBERG ROBERT | Director | Option exercise | 25,000 | $2.22 |
| 2026-10-06 | HERSHBERG ROBERT | Director | Open market sale | 25,000 | $5.00 |
| 2026-10-01 | Dar Zavain | Director | Grant / award | 4,607 | $0.00 |
| 2026-10-01 | Li Dean Y | Director | Grant / award | 3,378 | $0.00 |
| 2026-09-15 | Taylor Ben R | Chief Financial Officer | Tax withholding | 5,396 | $3.41 |
| 2026-09-08 | Khan Najat | CEO and President | Open market sale | 22,408 | $3.52 |
| 2026-09-01 | Borgeson Blake | Director | Open market sale | 30,000 | $3.34 |
| 2026-08-17 | Khan Najat | CEO and President | Tax withholding | 80,498 | $3.16 |
| 2026-08-17 | Hallett David | Chief Scientific Officer | Tax withholding | 26,657 | $3.16 |
| 2026-08-17 | Taylor Ben R | Chief Financial Officer | Tax withholding | 25,018 | $3.16 |
| 2026-08-04 | Borgeson Blake | Director | Open market sale | 30,000 | $3.25 |
| 2026-07-07 | Borgeson Blake | Director | Open market sale | 40,000 | $3.96 |
| 2026-07-01 | Dar Zavain | Director | Grant / award | 5,109 | $0.00 |
| 2026-07-01 | Li Dean Y | Director | Grant / award | 3,747 | $0.00 |
| 2026-06-18 | Bumpus Namandje | Director | Open market sale | 3,963 | $3.18 |
| 2026-06-17 | Borgeson Blake | Director | Grant / award | 88,424 | $0.00 |
| 2026-06-17 | HERSHBERG ROBERT | Director | Grant / award | 88,424 | $0.00 |
| 2026-06-17 | Michor Franziska | Director | Grant / award | 88,424 | $0.00 |
| 2026-06-17 | Sun Elaine D | Director | Grant / award | 88,424 | $0.00 |
| 2026-06-17 | Dar Zavain | Director | Grant / award | 88,424 | $0.00 |
| 2026-06-17 | Li Dean Y | Director | Grant / award | 88,424 | $0.00 |
| 2026-06-17 | Bumpus Namandje | Director | Grant / award | 88,424 | $0.00 |
| 2026-06-15 | Taylor Ben R | Chief Financial Officer | Tax withholding | 5,396 | $3.15 |
| 2026-06-05 | Gibson Christopher | Director | Derivative conversion | 40,000 | $0.00 |
| 2026-06-05 | Gibson Christopher | Director | Open market sale | 40,000 | $3.62 |
| 2026-06-05 | Khan Najat | CEO and President | Open market sale | 23,588 | $3.58 |
| 2026-06-03 | Bumpus Namandje | Director | Open market sale | 4,386 | $3.54 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:56 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-15 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-21 | 8-K | 2026-09-15 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-09-01 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
Recent news
Headlines about RXRX (Recursion Pharmaceuticals, Inc. Class A). Links open the publisher — we don’t host full articles.
-
Sanofi Drug Option Might Change The Case For Investing In Recursion Stock (RXRX)
Simply Wall Street · 2026-10-20 -
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
Yahoo · 2026-10-20 -
RXRX Nov 2026 1.000 call (RXRX261106C00001000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-19 -
RXRX Stock Pops As Sanofi Deal, ARK Buying Ignite Momentum
StocksToTrade · 2026-10-19 -
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target
Benzinga · 2026-10-19 -
Has Recursion Pharmaceuticals (RXRX) Fallen Far Enough on Sales?
Yahoo · 2026-10-19 -
Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone
Yahoo · 2026-10-19 -
Is Recursion Pharmaceuticals (RXRX) Undervalued Following Sanofi’s First Option Milestone?
Yahoo · 2026-10-19
No headlines in this category right now — try “All”.